Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Apr 5;19(8):1558–1568. doi: 10.1038/mt.2011.29

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2011 The American Society of Gene & Cell Therapy

This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/

PMC Copyright notice

Therapeutic efficacy of combination therapy based on the dendritic cells (DC) maturation, treatment schedule, and tumor size. (a) Tumor-bearing mice were treated with Ad-ΔB7/IL12/GMCSF in combination with mature or immature DCs. Similar antitumor effects were observed in combination therapies using mature or immature DCs. (b,c) Effect of the treatment schedule of oncolytic adenovirus and DCs on antitumor efficacy. Tumors were treated with Ad-ΔB7/IL12/GMCSF prior to DC vaccination (filled triangles), Ad-ΔB7/IL12/GMCSF and DCs on alternating days (open diamonds), or Ad-ΔB7/IL12/GMCSF after DC vaccination (filled squares). Tumor treatment with Ad-ΔB7/IL12/GMCSF prior to DC vaccination induced the most potent antitumor efficacy. (d,e) Antitumor effect of combination therapies on large tumors. High-dose combination therapy induced potent antitumor effect on large tumors. Data points represent the mean ± SE. All results in this figure represent results of at least six mice per group. *P < 0.05; **P < 0.01. GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin.